Systematic review with meta‐analysis: recurrence of hepatocellular carcinoma following direct‐acting antiviral therapy

Summary Background Although studies suggest decreased incident hepatocellular carcinoma (HCC) after direct‐acting antivirals (DAA), data are conflicting regarding HCC recurrence and aggressiveness in patients who have a history of HCC with complete response. Aim Characterize HCC recurrence patterns...

Full description

Saved in:
Bibliographic Details
Published in:Alimentary pharmacology & therapeutics 2018-07, Vol.48 (2), p.127-137
Main Authors: Saraiya, N., Yopp, A. C., Rich, N. E., Odewole, M., Parikh, N. D., Singal, A. G.
Format: Article
Language:English
Subjects:
Adult
Antiviral agents
Antiviral Agents - therapeutic use
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - epidemiology
Carcinoma, Hepatocellular - pathology
Carcinoma, Hepatocellular - virology
Female
Hepatitis C, Chronic - complications
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - epidemiology
Hepatitis C, Chronic - pathology
Hepatocellular carcinoma
Humans
Interferon
Liver cancer
Liver Neoplasms - drug therapy
Liver Neoplasms - epidemiology
Liver Neoplasms - pathology
Liver Neoplasms - virology
Male
Meta-analysis
Middle Aged
Neoplasm Recurrence, Local - epidemiology
Patients
Prospective Studies
Recurrence
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background Although studies suggest decreased incident hepatocellular carcinoma (HCC) after direct‐acting antivirals (DAA), data are conflicting regarding HCC recurrence and aggressiveness in patients who have a history of HCC with complete response. Aim Characterize HCC recurrence patterns after DAA therapy. Methods Two reviewers searched MEDLINE and SCOPUS from January 2015 to December 2017 and identified studies evaluating HCC recurrence patterns following DAA therapy. A pooled estimate was calculated using the DerSimonian and Laird method for a random effects model. The study was conducted in accordance with PRISMA guidelines. Results Among 24 studies (n = 1820 patients), the proportion of patients with HCC recurrence following DAA therapy ranged from 0% to 59% (pooled estimate 24.4%; 95% CI: 18.4%‐30.4%). Among 11 full text manuscripts, pooled HCC recurrence was 21.9% (95% CI: 16.2%‐28.3%). Factors associated with recurrence included history of prior HCC recurrence and a shorter interval between HCC complete response and DAA initiation. Nine studies comparing DAA‐treated and interferon‐treated or untreated patients found similar recurrence among DAA‐treated patients. Most (77.8%) patients with HCC recurrence were detected at an early tumour stage, of whom 64.7% received curative treatment. Study limitations included heterogeneous cohorts, potential misclassification of HCC absence prior to DAA, ascertainment bias for recurrence, and short durations of follow‐up. Conclusions Current data suggest acceptable HCC recurrence rates after DAA therapy, particularly if DAA therapy is delayed at least 6 months after HCC complete response. However, data characterising HCC recurrence after DAA therapy are of limited quality, highlighting the need for high quality prospective studies.
ISSN:0269-2813
1365-2036
DOI:10.1111/apt.14823